Safety Evaluation of an Expedited Omalizumab Home Self-Administration Pathway

Hussain, Zobia; Devlin, Lisa

doi:10.7759/cureus.19434

Cited by 2 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herein, we showed that the scheduled dose of the biologic therapy could be administered on time in patients with SARS‐CoV‐2 infection, as the treatment did not result in serious AEs or outcomes. Moreover, in line with previous studies, we provided the evidence that home self‐administration of mAbs was safe even in patients with SARS‐Cov‐2 infection 12,13 …”

Section: Discussionsupporting

confidence: 87%

“…In conclusion, our study suggests that the use of mAbs is safe Therefore, patients should be trained for a safe self-administration, also during SARS-CoV-2 infection. 4,13 Nevertheless, our study has several limitations. First, molecular tests were performed only in symptomatic patients.…”

Section: Discussionmentioning

confidence: 86%

“…Moreover, in line with previous studies, we provided the evidence that home self-administration of mAbs was safe even in patients with SARS-Cov-2 infection. 12,13 Asthma, involving lower airways, has been widely investigated as a risk factor for severe clinical outcomes in patients with SARS-CoV-2 infection. However, when compared with other comorbidities (e.g., obesity, diabetes, etc.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, the adoption of the self‐administration can contribute to decrease chances of viral exposure in the clinic. Therefore, patients should be trained for a safe self‐administration, also during SARS‐CoV‐2 infection 4,13 …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study

Manti

Giallongo

Pecora

et al. 2023

Pediatric Pulmonology

View full text Add to dashboard Cite

Background Asthma guidelines have recommended continuing treatment with biologics during coronavirus disease 2019 (COVID‐19) pandemic. However, a continuation of treatment with biologics in patients with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been little investigated. Objective To assess the safety of biologics in patients with SARS‐CoV‐2 infection. Methods A pilot, monocentric, prospective study. Patients aged 6 years old and older with severe asthma on treatment with biologics and confirmed SARS‐CoV‐2 infection were enrolled. Patients were followed‐up with periodic calls at different time points up to 3 months to detect any adverse effect and its relationship with biologic treatment according to the Naranjo Adverse Probability Scale (NAPS). The severity of SARS‐CoV‐2 infection and clinical outcome were also assessed. Results Overall, we included 21 patients (10 on therapy with omalizumab, 9 with dupilumab, and 2 with mepolizumab). Only a patient‐reported two local adverse events. No other adverse event was reported. Twenty out of 21 patients had a mild COVID‐19 course, and no adverse outcome was observed. Conclusion We showed that the scheduled dose of the biologic therapy can be administered safely on time in patients with SARS‐CoV‐2 infection, as the treatment did not result in adverse events or outcomes.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations